Minoan Group jumps as it signs exclusivity deal for sale of Travel & Leisure division
A look at some of the biggest risers and fallers in London on Tuesday
Company
Sareum Holdings PLC
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 8 of 12
Sareum update reveals extent of progress made by co's licence partner
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
Sareum Holdings: Sierra has ‘significantly expanded’ clinical development programme for its cancer drug
Sierra Oncology has announced ‘noteworthy progresses’ in the Dose Escalation Phase 1 portions for both of its ongoing Phase I/II clinical trials evaluating its potential best-in-class Chk1 inhibitor, SRA737
Archive
Proactive news snapshot: Strategic Minerals, Chariot Oil & Gas, dotdigital Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Sareum Holdings, Tlou Energy, Stobart Group
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum Holdings: Pre-clinical data for new cancer combination to be presented to US peers
US firm Sierra Oncology, which has exclusively licensed Sareum's cancer candidate SRA737, will demonstrate that the molecule synergizes with niraparib
Investments and investor services
FTSE 100 closes in red, despite US market turnaround
In London, the FTSE 100 closed down around 29 points at 7,252
Archive
Proactive news snapshot: Horse Hill, Kromek Group, Base Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Fusion Antibodies up another 30% after posting a 35% leap on Monday's AIM debut
A look at some of the biggest risers and fallers in London on Tuesday
Sareum soars as it secures Chinese and Japanese patents for TYK2 inhibitors
European patents were granted back in 2014 and the cancer drug discovery firm expects the US and other major markets to follow suit “in due course”
FTSE 100 closes in positive territory but off session highs
The UK blue chip index closed around seven points higher at 7,544, below the day’s peak of 7,563
Sareum hails year of progress as it readies for another key period in its development
The AIM-listed group, whose focus is cancer and autoimmune diseases, licensed its SRA737 to US firm Sierra Oncology just over a year ago
Archive
Proactive news snapshot: Synairgen, Iofina, Atlantis Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Scancell Holdings soars after "stunning endorsement" of its ImmunoBody platform
Cancer Research UK was immensely impressed with the company and its technology
Sareum chairman hails “year of significant progress” and looks ahead to busy 2018
Chairman Stephen Parker will tell investors at today’s AGM that Sareum has enjoyed a “transformational” year
Archive
Proactive news spotlight - Xtract Resources, Directa Plus, IronRidge Resources, Avation, BOS GLOBAL, appScatter, Akers Biosciences, Belvoir Lettings
It was another busy day for London's junior miners, drug developers and technology groups.
Sareum announces £700,000 fundraising to support drug development programmes
The company placed 100 mln new ordinary shares of 0.025p each at a price of 0.7p per share
Archive
Proactive news snapshot: Wolf Minerals , Sareum Holdings, ReNeuron Group …
A glance at some of the day's highlights from the Proactive Investors newswire